PPD (NASDAQ: PPD) is one of 35 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its rivals? We will compare PPD to related companies based on the strength of its dividends, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.
Insider and Institutional Ownership
51.1% of shares of all “Commercial physical research” companies are owned by institutional investors. 17.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares PPD and its rivals gross revenue, earnings per share (EPS) and valuation.
PPD has higher revenue, but lower earnings than its rivals. PPD is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and recommmendations for PPD and its rivals, as reported by MarketBeat.com.
||Strong Buy Ratings
PPD presently has a consensus price target of $32.46, indicating a potential upside of 85.49%. As a group, “Commercial physical research” companies have a potential upside of 51.17%. Given PPD’s stronger consensus rating and higher possible upside, research analysts clearly believe PPD is more favorable than its rivals.
This table compares PPD and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
PPD beats its rivals on 8 of the 11 factors compared.
PPD Company Profile
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The Laboratory Services segment offers bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. The company operates in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.